Neues "Wundermittel" jetzt bestellbar: "Star Scientific Launches Anatabloc(tm) Dietary Supplement" - 500 Beiträge pro Seite
eröffnet am 31.08.11 09:55:02 von
neuester Beitrag 05.10.11 07:19:45 von
neuester Beitrag 05.10.11 07:19:45 von
Beiträge: 15
ID: 1.168.698
ID: 1.168.698
Aufrufe heute: 0
Gesamt: 1.787
Gesamt: 1.787
Aktive User: 0
ISIN: US7720812046 · WKN: A14RTV
0,0001
USD
0,00 %
0,0000 USD
Letzter Kurs 09.02.23 Nasdaq OTC
Werte aus der Branche Getränke/Tabak
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5.300,00 | +99.999,00 | |
| 1,4600 | +21,67 | |
| 36,97 | +11,46 | |
| 2.040,45 | +9,72 | |
| 1,8450 | +9,17 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1.109,85 | -5,40 | |
| 1,4000 | -6,67 | |
| 5,7675 | -9,74 | |
| 1,1700 | -13,33 | |
| 0,7700 | -45,00 |
Feedback
Seit gestern kann das in einschlägigen US-boards viel diskutuierte neue "Wundermittel" ANATABLOC tatsächlich geordert werden: http://anatabloc.com/ . Wenn es das hält, was erste Studien andeuten, könnte dies eine Riesenchance sein, von Anfang an von dem Erfolg zu partizipieren (s. u. http://www.rfdn.org/inflammaging3.html )
Hier die komplette Meldung: http://www.istockanalyst.com/business/news/5386833/star-scie…
GLEN ALLEN, Va., Aug. 31, 2011 /PRNewswire-Asia/ -- Star Scientific, Inc. (NASDAQ: CIGX) has announced that the company is pleased to initiate the launch today of Anatabloc(TM), a dietary supplement that is designed to support the immune system in maintaining healthy levels of inflammation. Anatabloc(TM), developed by the company's Rock Creek Pharmaceuticals subsidiary, is being launched via a dedicated website (www.anatabloc.com) where the product can be purchased. The product also can be purchased through a toll-free customer center (1-800-778-2031).
Anatabloc(TM) contains the dietary ingredient anatabine citrate. Anatabine is an alkaloid that is found in a variety of plants in the Solinaceae family including the tobacco plant as well as in eggplant, green peppers and green tomatoes. Anatabine citrate, combined with Vitamins A and D3, is believed to assist the body in maintaining anti-inflammatory support. Excess inflammation is linked with a variety of auto-immune conditions that include thyroid dysfunction and arthritis. A provisional patent application has been filed with the US Patent & Trademark Office for the Anatabloc(TM) product.
As the company noted in an earlier release, a human trial examining the role of Anatabloc(TM) in subjects who are at risk for excessive inflammation is currently being conducted (the FIint study). Another human trial, conducted by Rock Creek, will begin in late September, and the company expects that a third trial, to be overseen by researchers at the University of Pisa, will begin during the fourth quarter.
A group of Richmond area physicians and healthcare providers are gathering at the Virginia Governor’s mansion today to learn more about the state of the research on Anatabloc(TM). The lead researchers who have overseen pre-clinical studies will discuss the results of testing with this group. They will be joined by researchers from the University of Virginia Medical School and the VCU Medical Center who also are interested in studying further potentials for Anatabloc(TM). Rock Creek has solicited research proposals from these institutions, and expects to issue planning grants for the preparation of full research proposals. The company anticipates that several of the planning grants will be announced today. Jonnie R. Williams, Star Scientific CEO, commented: “The tobacco plant led the way in growing the economy of the Commonwealth of Virginia 400 years ago. As a Virginia-based company, we now want to lead the way in understanding how the tobacco plant can yield important benefits to human health.”
Anatabloc(TM) is the second dietary supplement to be developed by Rock Creek."
Hier die komplette Meldung: http://www.istockanalyst.com/business/news/5386833/star-scie…
GLEN ALLEN, Va., Aug. 31, 2011 /PRNewswire-Asia/ -- Star Scientific, Inc. (NASDAQ: CIGX) has announced that the company is pleased to initiate the launch today of Anatabloc(TM), a dietary supplement that is designed to support the immune system in maintaining healthy levels of inflammation. Anatabloc(TM), developed by the company's Rock Creek Pharmaceuticals subsidiary, is being launched via a dedicated website (www.anatabloc.com) where the product can be purchased. The product also can be purchased through a toll-free customer center (1-800-778-2031).
Anatabloc(TM) contains the dietary ingredient anatabine citrate. Anatabine is an alkaloid that is found in a variety of plants in the Solinaceae family including the tobacco plant as well as in eggplant, green peppers and green tomatoes. Anatabine citrate, combined with Vitamins A and D3, is believed to assist the body in maintaining anti-inflammatory support. Excess inflammation is linked with a variety of auto-immune conditions that include thyroid dysfunction and arthritis. A provisional patent application has been filed with the US Patent & Trademark Office for the Anatabloc(TM) product.
As the company noted in an earlier release, a human trial examining the role of Anatabloc(TM) in subjects who are at risk for excessive inflammation is currently being conducted (the FIint study). Another human trial, conducted by Rock Creek, will begin in late September, and the company expects that a third trial, to be overseen by researchers at the University of Pisa, will begin during the fourth quarter.
A group of Richmond area physicians and healthcare providers are gathering at the Virginia Governor’s mansion today to learn more about the state of the research on Anatabloc(TM). The lead researchers who have overseen pre-clinical studies will discuss the results of testing with this group. They will be joined by researchers from the University of Virginia Medical School and the VCU Medical Center who also are interested in studying further potentials for Anatabloc(TM). Rock Creek has solicited research proposals from these institutions, and expects to issue planning grants for the preparation of full research proposals. The company anticipates that several of the planning grants will be announced today. Jonnie R. Williams, Star Scientific CEO, commented: “The tobacco plant led the way in growing the economy of the Commonwealth of Virginia 400 years ago. As a Virginia-based company, we now want to lead the way in understanding how the tobacco plant can yield important benefits to human health.”
Anatabloc(TM) is the second dietary supplement to be developed by Rock Creek."
Hilft das gegen Fusspilz 
Antwort auf Beitrag Nr.: 42.024.720 von Loserin am 31.08.11 09:58:13Das Zeugs ist in jeder Zigarette.
Hilft vielleicht in sofern gegen Fußpilz, dass bei starken Rauchern irgendwann der Fuß amputiert werden muss.
Hilft vielleicht in sofern gegen Fußpilz, dass bei starken Rauchern irgendwann der Fuß amputiert werden muss.
Antwort auf Beitrag Nr.: 42.024.720 von Loserin am 31.08.11 09:58:13Wenn Fußpilz zu den chronischen Entzündungen gehört, dann ja 
Im Ernst: das Mittel soll gegen chronische Entzündungen, die man häufig in sich trägt ohne es zu wissen, extrem gut helfen.
Viele Erkrankungen enstehen bzw. werden durch solche chronischen Entzündungen begünstigt: Herzkrankheiten, Diabetes, Asthma, Alzheimer, rheumatoide Arthritis...
(s. http://anatabloc.com/how-anatabloc-works/ )
Im Ernst: das Mittel soll gegen chronische Entzündungen, die man häufig in sich trägt ohne es zu wissen, extrem gut helfen.
Viele Erkrankungen enstehen bzw. werden durch solche chronischen Entzündungen begünstigt: Herzkrankheiten, Diabetes, Asthma, Alzheimer, rheumatoide Arthritis...
(s. http://anatabloc.com/how-anatabloc-works/ )
Antwort auf Beitrag Nr.: 42.024.790 von AdHick am 31.08.11 10:13:43Yep, ist u.a. in Tabak enthalten das zum Einsatz kommende Alkaloid: "It’s ironic that a compound with the potential medical benefits of Anatabloc™ was hidden in tobacco." (Roskamp Institute Director, Dr. Michael Mullan)
Trading Spotlight
Antwort auf Beitrag Nr.: 42.024.816 von alex1975 am 31.08.11 10:17:51"is believed to assist"
Wolkiger geht's wohl kaum.
Nachweise scheint es (noch) nicht zu geben.
Etwas für KamikazeAnleger.
Wolkiger geht's wohl kaum.
Nachweise scheint es (noch) nicht zu geben.
Etwas für KamikazeAnleger.
Antwort auf Beitrag Nr.: 42.024.790 von AdHick am 31.08.11 10:13:43ich rauche nicht mehr.
Hab ich deswegen Fusspilz ?
Hab ich deswegen Fusspilz ?
Antwort auf Beitrag Nr.: 42.024.891 von Loserin am 31.08.11 10:30:01Möglich.
Viele Abhängige lenken sich mit dem Sammeln von Pilzen vom Entzug ab.
Viele Abhängige lenken sich mit dem Sammeln von Pilzen vom Entzug ab.
Antwort auf Beitrag Nr.: 42.024.857 von AdHick am 31.08.11 10:24:42ja, deswegen habe ich ja Wundermittel auch in Anführungszeichen gesetzt. Ich war zumindest schon mal positiv überrascht, dass ein vermarktbares Produkt am Start ist. Auch der Rahmen der Launch-Veranstaltung deutet drauf hin, dass irgendwas dran sein könnte an dem Mittelchen - fand immerhin im Virginia Governor’s mansion statt und nicht bei Mc Donalds... es ist doch eher unwahrscheinlich, dass ein Gouverneur einfach so seinen guten Namen aufs Spiel setzt und so ein Event hostet.
es ist doch eher unwahrscheinlich, dass ein Gouverneur einfach so seinen guten Namen aufs Spiel setzt und so ein Event hostet.
Also wenn schon über die Aktie gesprochen wird sollte man erst einmal mit dem negativen Anfangen.
Da gab es letzten Freitag einen starken Kursrutsch unter sehr hohem Volumen nach schlechten NEWS:
Star Scientific Loses New Trial Bid in Reynolds Tobacco Case
Q
By Susan Decker - Aug 26, 2011 8:34 PM GMT+0200
Star Scientific Inc. tumbled the most in two years after losing a bid for a new trial in its decade-long effort to extract patent royalties from Reynolds American Inc. (RAI) on way to reduce carcinogens in cigarettes.
While the U.S. Court of Appeals for the Federal Circuit in Washington today upheld the validity of two Star patents, the panel said there was no need to retry the infringement case against Reynolds that Star lost in 2009. Chief Circuit Judge Randall Rader said in the 2-1 opinion that a new trial wouldn’t change the outcome as “there was substantial untainted evidence before the jury to support a verdict of non-infringement.”
The patents cover a curing process that prevents “bacterial activity” in tobacco leaves, resulting in the lowest levels of cancer causing nitrosamines, according to Star. The money-losing company, which had less than $1 million in sales last year, has “not been able to monetize their only asset,” Martin Shkreli, chief investment officer of New York- based hedge fund MSMB Capital Management, said after the ruling.
“This is a complete loss for Star and basically makes their business worthless,” said Shkreli, who has trading positions that bet on the stock falling. “Investors have been down this litigation road with Star for five to 10 years and it’s never been fruitful.”
Shares Fall
Star whipsawed in Nasdaq Stock Market trading after the ruling was made public, rising as much as 32 percent before tumbling the most since June 2009. The shares fell $1.45, or 48 percent, to $1.55 at 2:12 p.m. New York time.
The Glen Allen, Virginia-based company said it’s considering options for “further appellate review.” Star said the validity ruling will allow it to pursue claims “against all prior and future infringers,” including another case it has against Reynolds that had been put on hold pending this appeal.
“We intend to vigorously protect our intellectual property, which we consider to be among our corporate crown jewels,” Star Chairman and President Paul L. Perito said in a statement today.
Star had claimed Reynolds was unable on its own to reduce nitrosamines in tobacco as much as Star could. Star said Reynolds then chose to use the technology without permission as part of an effort to “neutralize” competition. Reynolds denied the claim, challenging validity of the patents.
“We’re very pleased with today’s ruling,” August Borschke, chief patent counsel for R.J. Reynolds Tobacco, said in an e-mail. “R.J. Reynolds did not infringe Star’s patents.”
Patent Office Review
R.J. Reynolds Tobacco is the cigarette unit of Winston- Salem, North Carolina-based Reynolds American, the second- largest U.S. tobacco company. Reynolds makes Camel, Winston and Salem brand cigarettes.
The case initially had been thrown out in June 2007 after U.S. District Judge Marvin Garbis said Star deceived the U.S. Patent and Trademark Office to obtain formal rights to the invention. The appeals court reversed that order, setting the stage for the 2009 trial.
The case is Star Scientific v. R.J. Reynolds Tobacco Co., 10-1183, U.S. Court of Appeals for the Federal Circuit (Washington). The lower court case is Star Scientific Inc. (CIGX) v. R.J. Reynolds Tobacco Co., 01cv1504, U.S. District Court, District of Maryland (Greenbelt).
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net
To contact the editor responsible for this story: Allan Holmes at aholmes25@bloomberg.net
Want to save this for later? Add it to your Queue!
Da gab es letzten Freitag einen starken Kursrutsch unter sehr hohem Volumen nach schlechten NEWS:
Star Scientific Loses New Trial Bid in Reynolds Tobacco Case
Q
By Susan Decker - Aug 26, 2011 8:34 PM GMT+0200
Star Scientific Inc. tumbled the most in two years after losing a bid for a new trial in its decade-long effort to extract patent royalties from Reynolds American Inc. (RAI) on way to reduce carcinogens in cigarettes.
While the U.S. Court of Appeals for the Federal Circuit in Washington today upheld the validity of two Star patents, the panel said there was no need to retry the infringement case against Reynolds that Star lost in 2009. Chief Circuit Judge Randall Rader said in the 2-1 opinion that a new trial wouldn’t change the outcome as “there was substantial untainted evidence before the jury to support a verdict of non-infringement.”
The patents cover a curing process that prevents “bacterial activity” in tobacco leaves, resulting in the lowest levels of cancer causing nitrosamines, according to Star. The money-losing company, which had less than $1 million in sales last year, has “not been able to monetize their only asset,” Martin Shkreli, chief investment officer of New York- based hedge fund MSMB Capital Management, said after the ruling.
“This is a complete loss for Star and basically makes their business worthless,” said Shkreli, who has trading positions that bet on the stock falling. “Investors have been down this litigation road with Star for five to 10 years and it’s never been fruitful.”
Shares Fall
Star whipsawed in Nasdaq Stock Market trading after the ruling was made public, rising as much as 32 percent before tumbling the most since June 2009. The shares fell $1.45, or 48 percent, to $1.55 at 2:12 p.m. New York time.
The Glen Allen, Virginia-based company said it’s considering options for “further appellate review.” Star said the validity ruling will allow it to pursue claims “against all prior and future infringers,” including another case it has against Reynolds that had been put on hold pending this appeal.
“We intend to vigorously protect our intellectual property, which we consider to be among our corporate crown jewels,” Star Chairman and President Paul L. Perito said in a statement today.
Star had claimed Reynolds was unable on its own to reduce nitrosamines in tobacco as much as Star could. Star said Reynolds then chose to use the technology without permission as part of an effort to “neutralize” competition. Reynolds denied the claim, challenging validity of the patents.
“We’re very pleased with today’s ruling,” August Borschke, chief patent counsel for R.J. Reynolds Tobacco, said in an e-mail. “R.J. Reynolds did not infringe Star’s patents.”
Patent Office Review
R.J. Reynolds Tobacco is the cigarette unit of Winston- Salem, North Carolina-based Reynolds American, the second- largest U.S. tobacco company. Reynolds makes Camel, Winston and Salem brand cigarettes.
The case initially had been thrown out in June 2007 after U.S. District Judge Marvin Garbis said Star deceived the U.S. Patent and Trademark Office to obtain formal rights to the invention. The appeals court reversed that order, setting the stage for the 2009 trial.
The case is Star Scientific v. R.J. Reynolds Tobacco Co., 10-1183, U.S. Court of Appeals for the Federal Circuit (Washington). The lower court case is Star Scientific Inc. (CIGX) v. R.J. Reynolds Tobacco Co., 01cv1504, U.S. District Court, District of Maryland (Greenbelt).
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net
To contact the editor responsible for this story: Allan Holmes at aholmes25@bloomberg.net
Want to save this for later? Add it to your Queue!
Antwort auf Beitrag Nr.: 42.025.101 von Stammzelle01 am 31.08.11 11:01:02richtig, am montag nach dem kursrutsch am freitag ging es auch direkt wieder über 40% nach oben - die haben zwar verloren, was die tatsache angeht, eine patentsverletzung nachzuweisen - aber das gericht hat die patente gleichzeitig für rechtskräftig erklärt (Reynolds hatte versucht diese im Rahmen des Verfahrens als ungültig darzustellen). Aber trotzdem wäre es natürlich schöner gewesen, direkt in diesem Verfahren scho nein paar "Milliönchen" abzuholen - die Frage ist halt die, ob man auf den Prozessgewinn sepkuliert hat, oder auf zukünftige Klagen oder den Erfolg von dem Anatabloc Zeug setzt.
Obs dem Anwender nutzt?
Diese Lebensmittelzusätze sind meistens für die Katz.
Besser auf eine vernünftige Ernährung achten.
Bei Pilzbefall halt kein Zucker, Honig, Eis, Cola-Candida,
Süßstoffe usw.
Aber Nutzen haben auf jedem Fall die Verkäufer.
Diese Lebensmittelzusätze sind meistens für die Katz.
Besser auf eine vernünftige Ernährung achten.
Bei Pilzbefall halt kein Zucker, Honig, Eis, Cola-Candida,
Süßstoffe usw.
Aber Nutzen haben auf jedem Fall die Verkäufer.
mag alles sein - es ist aber ggfs. doch was positives dran an dem, was die machen 
!
dazu auch eine meldung von heute, der Tradewinds Master Fund (BVI) Ltd. hält mittlerweile 17% an dem laden, tendenz steigend
http://www.sec.gov/Archives/edgar/data/776008/00011931251123…
! dazu auch eine meldung von heute, der Tradewinds Master Fund (BVI) Ltd. hält mittlerweile 17% an dem laden, tendenz steigend
http://www.sec.gov/Archives/edgar/data/776008/00011931251123…
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=CIGX:… 
Star Scientific Reports First Peer-Reviewed Article on Anatabine and
Alzheimer's Disease by Roskamp Institute
GLEN ALLEN, Virginia, October 4, 2011 /PRNewswire/ --
Star Scientific, Inc. (Nasdaq: CIGX) reports today the publication of the
first peer-reviewed article on the in-vitro and in-vivo activity of anatabine
in Alzheimer's Disease. The article is authored by scientists at the Roskamp
Institute and is electronically published in the European Journal of
Pharmacology (2011 Sept 19). It states that anatabine lowers Alzheimer's
A-beta production in-vitro and in-vivo.
In the article the authors describe the accumulation of an abnormal substance,
called A-beta, the substance that leads to amyloid formation and damage to
brain tissue. They studied the formation of A-beta and showed how anatabine
lowers levels of two forms of A-beta (1-40 and 1-42) in a dose-dependent
manner, possibly by preventing or reducing formation from the precursor
protein. After showing the activity in the test tube, the researchers went on
to show that when anatabine is given to mice vulnerable to accumulation of
amyloid, treatment with anatabine lowers brain levels of both A-beta (1-40)
and A-beta (1-42), postulated to be due to effects on NFKB activation. Michael
Mullan, MD, Ph.D., Roskamp Institute co-director and one of the article's
authors, commented, "This paper demonstrates anatabine's potential as an
anti-inflammatory agent and shows it may have broad applications including for
disorders like Alzheimer's Disease."
Anatabine citrate is one of the active ingredients in Anatabloc™, a dietary
supplement developed by Star Scientific's subsidiary, Rock Creek
Pharmaceuticals. Anatabloc™, which entered the market on August 30, is
designed to provide anti-inflammatory support ( http://www.anatabloc.com ).
Curtis Wright, MD, MPH, Senior Vice President of Rock Creek Pharmaceuticals,
expressed his opinion of the Roskamp findings. "While we were aware that
Roskamp was conducting studies of the effects of dietary supplementation with
anatabine in Alzheimer's Disease, it is gratifying that external peer review
validated the work they have done. The research confirms that this natural
plant compound shows an interesting regulatory effect on brain immune
responses. It is one thing to believe your own results; it is quite another to
have them accepted by your peers in the scientific community." Anatabine for
the Roskamp research was provided through Rock Creek Pharmaceuticals.
Ongoing human clinical studies of anatabine citrate, and the commercial
product Anatabloc™, are examining the potential role of nutritional
supplementation in regulating low-level inflammation controlled by the NFκB
system.
Star Scientific Reports First Peer-Reviewed Article on Anatabine and
Alzheimer's Disease by Roskamp Institute
GLEN ALLEN, Virginia, October 4, 2011 /PRNewswire/ --
Star Scientific, Inc. (Nasdaq: CIGX) reports today the publication of the
first peer-reviewed article on the in-vitro and in-vivo activity of anatabine
in Alzheimer's Disease. The article is authored by scientists at the Roskamp
Institute and is electronically published in the European Journal of
Pharmacology (2011 Sept 19). It states that anatabine lowers Alzheimer's
A-beta production in-vitro and in-vivo.
In the article the authors describe the accumulation of an abnormal substance,
called A-beta, the substance that leads to amyloid formation and damage to
brain tissue. They studied the formation of A-beta and showed how anatabine
lowers levels of two forms of A-beta (1-40 and 1-42) in a dose-dependent
manner, possibly by preventing or reducing formation from the precursor
protein. After showing the activity in the test tube, the researchers went on
to show that when anatabine is given to mice vulnerable to accumulation of
amyloid, treatment with anatabine lowers brain levels of both A-beta (1-40)
and A-beta (1-42), postulated to be due to effects on NFKB activation. Michael
Mullan, MD, Ph.D., Roskamp Institute co-director and one of the article's
authors, commented, "This paper demonstrates anatabine's potential as an
anti-inflammatory agent and shows it may have broad applications including for
disorders like Alzheimer's Disease."
Anatabine citrate is one of the active ingredients in Anatabloc™, a dietary
supplement developed by Star Scientific's subsidiary, Rock Creek
Pharmaceuticals. Anatabloc™, which entered the market on August 30, is
designed to provide anti-inflammatory support ( http://www.anatabloc.com ).
Curtis Wright, MD, MPH, Senior Vice President of Rock Creek Pharmaceuticals,
expressed his opinion of the Roskamp findings. "While we were aware that
Roskamp was conducting studies of the effects of dietary supplementation with
anatabine in Alzheimer's Disease, it is gratifying that external peer review
validated the work they have done. The research confirms that this natural
plant compound shows an interesting regulatory effect on brain immune
responses. It is one thing to believe your own results; it is quite another to
have them accepted by your peers in the scientific community." Anatabine for
the Roskamp research was provided through Rock Creek Pharmaceuticals.
Ongoing human clinical studies of anatabine citrate, and the commercial
product Anatabloc™, are examining the potential role of nutritional
supplementation in regulating low-level inflammation controlled by the NFκB
system.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,07 | |
| -1,79 | |
| -1,63 | |
| +0,20 | |
| +0,26 | |
| -1,36 | |
| +0,26 | |
| -0,11 | |
| +2,31 | |
| +0,30 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 204 | ||
| 190 | ||
| 146 | ||
| 69 | ||
| 32 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 25 |
